A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy

Protocol: 
AAAQ6852
Phase: 
II

A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy

Are you Eligible? (Inclusion Criteria)

1. Subjects diagnosed with primary or secondary AML. In the case of AML from antecedent MDS, subjects should not have had prior treatment with a hypomethylating agent over the last 6 months

Part A:
1. Absence of rapidly progressing AML
OR
2. White blood cell count <= 40,000

Part B:
1. Previously untreated (except: emergency leukopheresis and/or hydroxyurea during the screening phase to control hyperleukocytosis);
2. Ineligible for standard intensive chemotherapy based on documented medical reasons.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States